Canada Life’s Pacific Biosciences PACB Stock Holding History

Canada Life’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34K	Buy	25,662 +5,382	+27%	+$9.63K	﹤0.01%	1802
2025 Q4	$38K	Buy	20,280 +582	+3%	+$1.12K	﹤0.01%	1809
2025 Q3	$25K	Buy	19,698 +5,364	+37%	+$7.26K	﹤0.01%	1865
2025 Q2	$18K	Sell	14,334 -21,408	-60%	-$24.7K	﹤0.01%	1914
2025 Q1	$42K	Buy	35,742 +4,650	+15%	+$7.13K	﹤0.01%	1878
2024 Q4	$56K	Buy	31,092 +5,935	+24%	+$11.6K	﹤0.01%	1880
2024 Q3	$43K	Buy	25,157 +768	+3%	+$1.26K	﹤0.01%	1958
2024 Q2	$33K	Sell	24,389 -65,717	-73%	-$133K	﹤0.01%	1999
2024 Q1	$337K	Buy	90,106 +1,270	+1%	+$7.44K	﹤0.01%	1757
2023 Q4	$867K	Buy	88,836 +6,689	+8%	+$54.7K	﹤0.01%	1545
2023 Q3	$685K	Buy	82,147 +16,552	+25%	+$189K	﹤0.01%	1598
2023 Q2	$876K	Buy	65,595 +5,484	+9%	+$66.6K	﹤0.01%	1534
2023 Q1	$697K	Sell	60,111 -1,036	-2%	-$10.3K	﹤0.01%	1607
2022 Q4	$502K	Buy	61,147 +25,883	+73%	+$223K	﹤0.01%	1720
2022 Q3	$204K	Buy	35,264 +24,629	+232%	+$141K	﹤0.01%	1858
2022 Q2	$47K	Buy	10,635 +150	+1%	+$911	﹤0.01%	2069
2022 Q1	$101K	Buy	10,485 +154	+1%	+$1.77K	﹤0.01%	1997
2021 Q4	$210K	Buy	10,331 +144	+1%	+$3.48K	﹤0.01%	1862
2021 Q3	$262K	Sell	10,187 -795	-7%	-$23.6K	﹤0.01%	1856
2021 Q2	$384K	Hold	10,982	–	–	﹤0.01%	1795
2021 Q1	$363K	Sell	10,982 -974	-8%	-$34.1K	﹤0.01%	1815
2020 Q4	$309K	Buy	11,956 +3,295	+38%	+$56K	﹤0.01%	1866
2020 Q3	$85K	Hold	8,661	–	–	﹤0.01%	2072
2020 Q2	$30K	Hold	8,661	–	–	﹤0.01%	2398
2020 Q1	$27K	Hold	8,661	–	–	﹤0.01%	2312
2019 Q4	$44K	Hold	8,661	–	–	﹤0.01%	2308
2019 Q3	$45K	Sell	8,661 -7,663	-47%	-$42.9K	﹤0.01%	1045
2019 Q2	$98K	Hold	16,324	–	–	﹤0.01%	2234
2019 Q1	$118K	Hold	16,324	–	–	﹤0.01%	2026
2018 Q4	$116K	Buy	16,324 +7,237	+80%	+$45.9K	﹤0.01%	2098
2018 Q3	$49K	Hold	9,087	–	–	﹤0.01%	2401
2018 Q2	$32K	Hold	9,087	–	–	﹤0.01%	2474
2018 Q1	$19K	Hold	9,087	–	–	﹤0.01%	2509
2017 Q4	$24K	Hold	9,087	–	–	﹤0.01%	2484
2017 Q3	$45K	Hold	9,087	–	–	﹤0.01%	2361
2017 Q2	$32K	Hold	9,087	–	–	﹤0.01%	2432
2017 Q1	$47K	Hold	9,087	–	–	﹤0.01%	2320
2016 Q4	$35K	Hold	9,087	–	–	﹤0.01%	2403
2016 Q3	$81K	Hold	9,087	–	–	﹤0.01%	2217
2016 Q2	$64K	Hold	9,087	–	–	﹤0.01%	2247
2016 Q1	$77K	Hold	9,087	–	–	﹤0.01%	1931
2015 Q4	$119K	Buy	+9,087	New	+$81.5K	﹤0.01%	1637
2015 Q3	–	Sell	-1,000	Closed	-$5K	–	2529
2015 Q2	$5K	Hold	1,000	–	–	﹤0.01%	2580
2015 Q1	$5K	Buy	+1,000	New	+$6.89K	﹤0.01%	2487

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Canada Life's PACB Position: Q1 2026 in Review

Canada Life increased its Pacific Biosciences (PACB) stake by 27% in Q1 2026, buying an estimated $9.63K and bringing the position to 25,662 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

Canada Life first reported a position in PACB in Q1 2015 and has held it in 44 quarters since. The position peaked at $876K in Q2 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Canada Life held 25,662 shares of Pacific Biosciences worth $34K as of Q1 2026.
Canada Life bought 5,382 Pacific Biosciences shares in Q1 2026, an estimated $9.63K.
Pacific Biosciences made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1802 holding.
Canada Life first reported a position in Pacific Biosciences in Q1 2015 and has held it in 44 quarters since.
Canada Life's Pacific Biosciences position peaked at $876K in Q2 2023.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.